[Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia].

Abstract

OBJECTIVE:

To study the efficacy and safety of Eviprostat for the treatment of benign prostatic hyperplasia (BPH).

METHODS:

An open, multicentral clinical trial was conducted in 100 patients with BPH. Patients received a 12-week oral administration of Eviprostat 2 tablets per-time, 3 times a day. The main indexes of efficacy include international prostatic symptom score (IPSS), maximum urinary flow rate (Qmax), residual urine ( Ru) and prostatic volume (V). The additional indexes are quality of life score (QOL) and average urinary flow rate (Qave).

RESULTS:

After a 12-week therapy, IPSS, QOL score, Qmax and Qave were significantly improved. IPSS was averagely decreased by 5.67 (P < 0.001); QOL score was averagely decreased by 1.44 (P < 0.001); Qmax was averagely increased by 1.70 ml/s (P <0.001); Qave was averagely increased by 1.15 ml/s (P < 0.001); Ru was averagely decreased by 5.07 ml (P = 0.046) , PSA level was averagely decreased by 0.129 microg/L (P < 0.017). The clinical adverse event rate was 1%.

CONCLUSION:

Eviprostat is a kind of safe, effective and preferable drug for treating BPH. It can improve the subjective symptoms and objective measures of the patients.

• Authors: Yi Song, Ning-chen Li, Xiao-feng Wang, Lu-lin Ma, Ben Wan, Bao-fa Hong, Yan-qun Na
• Journal: Zhonghua nan ke xue = National journal of andrology (Zhonghua Nan Ke Xue) Vol. 11 Issue 9 Pg. 674-6 (Sep 2005) ISSN: 1009-3591 [Print] China
• PMID: 16209208 (Publication Type: English Abstract, Journal Article, Multicenter Study)

Chemical References

• Drug Combinations
• Plant Extracts
• Ethamsylate
• eviprostat

Topics

• Aged
• Aged, 80 and over
• Drug Combinations
• Ethamsylate (adverse effects, therapeutic use)
• Humans
• Male
• Middle Aged
• Plant Extracts (adverse effects, therapeutic use)
• Prostatic Hyperplasia (drug therapy)
• Quality of Life
• Treatment Outcome
• Urodynamics